Objective: The data available regarding the epithelial-mesenchymal transition (EMT) markers are little. This study aimed to evaluate the immunohistochemical expression of EMT markers; MYb-like, Swirm and Mpn domain-containing protein-1 (MYSM-1) and Twist-1 in renal cell carcinoma (RCC), in a trial to find their role in the prognosis of such type of cancer.
Methods: Immunoexpressions of MYb-like, Swirm and Mpn domaincontaining protein-1 (MYSM-1) and Twist-1 were assessed in tissue specimens of 50 patients with RCC, and correlated with other clinicopathological features. The findings and their correlations were statistically determined.
Results: Low expression of MYSM-1 was negatively correlated with size of the tumor, primary tumor (pT) stage, Fuhrman grade (P < 0.001), age (P = 0.002), and lymph node metastases (P = 0.010). Immunoexpression of MYSM-1 was significantly correlated with distant metastases (P = 0.004), overall survival (OS) (P < 0.001), and local recurrence (P = 0.001). High expression of Twist-1 was positively correlated with pT stage, Fuhrman grade, lymph node, distant metastases, age (P < 0.001), clinical stage (P = 0.002), the
presence of sarcomatous change (P = 0.004), and tumor size (P = 0.008). Immunoexpression of Twist-1 was significantly correlated with distant metastases (P = 0.009), OS (P < 0.001), and local recurrence (P = 0.003).
Conclusion: Overexpression of Twist-1 is an indication of poor prognosis in patients with RCC, whereas that of MYSM-1 is a marker of good prognosis.
Renal cell carcinoma, Immunohistochemical expression, MYSM-1, Twist-1, Prognosis